Venclexta (venetoclax) is a prescription drug that’s used to treat certain blood cancers. Venclexta comes as an oral tablet. Venclexta is used in adults to treat the following cancers in certain ...

Venclexta (venetoclax) is a prescription drug that’s used to treat certain forms of cancer. Venclexta’s cost may depend on factors such as your dosage, whether you have health insurance, and the ...

Venclexta (venetoclax) is a brand-name oral tablet that’s prescribed for certain types of blood cancers. The cost of the drug, with and without insurance, can depend on several factors, such as ...

Roche and AbbVie have come up short again in their effort to gain an additional indication for their blockbuster blood cancer treatment Venclexta. A phase 3 trial of the therapy in previously ...

Regardless of whether it was guided by minimal residual disease status or given at a fixed dosage, consolidation Venclexta proved to be beneficial in patients with chronic lymphocytic leukemia. There ...

What Is It, and Why Does It Matter? The FDA has approved a new combination treatment for adults with certain cancers of the blood and lymphatic system. The targeted regimen combines Calquence ...

The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic ...

– Every year in the United States, approximately 10,000 people are diagnosed with myelodysplastic syndromes (MDS), and there remains a high unmet need for new treatment options – – The designation is ...

NORTH CHICAGO, Ill., April 12, 2016 /PRNewswire/ -- AbbVie ABBV, a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of ...

Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed ...

Weeks after AbbVie and Roche's blood cancer med Venclexta flopped a confirmatory trial in acute myeloid leukemia (AML), the partners hoped for a win to keep their med's chances alive. Now, a Venclexta ...